What Are Nitrosamines — And Why Did They Become a Regulatory Crisis?
In 2018, a routine analysis by a European drug manufacturer revealed something alarming: a commonly prescribed blood pressure medication (valsartan) contained N-nitrosodimethylamine (NDMA) at concentrations far exceeding safe limits. What followed was one of the largest drug recalls in pharmaceutical history, affecting dozens of countries and millions of patients.
Nitrosamines are a class of chemical compounds with the general structure R₁N(NO)R₂. Many are classified as probable human carcinogens (Group 2A by IARC). Some, like NDMA, are known to cause liver, kidney, and respiratory tract tumours in animal studies.
The discovery of nitrosamines in pharmaceutical products — initially in sartan blood pressure medications, then in ranitidine (Zantac), metformin, and other drug classes — exposed a systemic gap: pharmaceutical manufacturers had not been specifically screening for these impurities, and regulatory guidelines had not explicitly required it.
That gap has now been decisively closed.
How Nitrosamines Form in Pharmaceuticals
Understanding nitrosamine formation is essential for both testing and risk assessment. Nitrosamines typically arise through:
Contaminated starting materials or reagents: Dimethylformamide (DMF) and dimethylacetamide (DMA) — common solvents in API synthesis — can degrade to dimethylamine, which reacts with nitrous acid to form NDMA.
Reaction conditions: Certain manufacturing steps, particularly those involving sodium nitrite (used in diazotisation reactions), can generate nitrosating agents that react with secondary amines present in the drug molecule or excipients.
Packaging materials: Sodium nitrite can leach from certain packaging components or desiccants, particularly in the presence of moisture.
Storage conditions: High temperature and humidity can accelerate nitrosamine formation post-manufacture, which is why stability testing at 40°C/75% RH revealed NDMA in many products years after their initial approval.
Intrinsic nitrosamine formation: Ranitidine (Zantac) was a unique case where the molecule itself was inherently unstable and generated NDMA as a self-degradation product, regardless of manufacturing conditions.
Regulatory Framework: FDA, EMA, CDSCO, and WHO
FDA Guidance
The US FDA issued its first guidance on nitrosamine impurities in August 2018, initially focused on sartan drugs. By 2020, FDA had expanded requirements to all human drug products. The current framework requires manufacturers to:
- Conduct a risk assessment for nitrosamine formation across all drug products
- Test for confirmed or possible nitrosamines using validated analytical methods
- Submit confirmatory testing data to FDA
- Implement manufacturing controls to prevent or minimise nitrosamine levels
FDA established Acceptable Intake (AI) limits for specific nitrosamines. These are the maximum daily intake (in nanograms) considered acceptable over a lifetime:
| Nitrosamine | FDA AI Limit | Common Source |
|---|---|---|
| NDMA (N-nitrosodimethylamine) | 96 ng/day | Sartans, ranitidine, metformin |
| NDEA (N-nitrosodiethylamine) | 26.5 ng/day | Sartans |
| NMBA (N-nitrosomethyl-n-butylamine) | 96 ng/day | Sartans |
| NIPEA (N-nitroso-N-isopropyl-ethylamine) | 26.5 ng/day | Sartans |
| NDIPA (N-nitrosodiisopropylamine) | 26.5 ng/day | Sartans |
| NDBA (N-nitrosodi-n-butylamine) | 26.5 ng/day | Sartans |
| NMPA (N-nitroso-methylphenylamine) | 26.5 ng/day | Drug-specific |
For drug-specific nitrosamines not on this list, manufacturers must derive AI limits using the Kroes TTC (Threshold of Toxicological Concern) approach or through compound-specific carcinogenicity data.
EMA Requirements
The European Medicines Agency has been particularly active on nitrosamine regulation. EMA’s guidance distinguishes between:
- Step 1: Risk assessment to identify if nitrosamines could be present
- Step 2: Confirmatory testing where risk assessment indicates possible presence
- Step 3: Change implementation if nitrosamines are confirmed above limits
EMA’s AI limits generally align with FDA’s but use slightly different calculation methodologies for drug-specific compounds. EMA also requires that nitrosamine risk assessments be documented in manufacturing authorisation dossiers.
WHO and CDSCO
WHO adopted AI limits consistent with FDA guidance in its 2021 guidance document on nitrosamine impurities. India’s CDSCO issued an advisory in 2021 directing Indian pharmaceutical manufacturers to implement nitrosamine risk assessments and testing, particularly for sartans, ranitidine, and metformin products.
ICH M7: The Genotoxic Impurity Framework
Nitrosamines fall within the broader framework of ICH M7 — Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk. ICH M7 applies to all impurities with structural alerts for mutagenicity, not just nitrosamines.
ICH M7 introduced the concept of the TTC (Threshold of Toxicological Concern) — a daily intake threshold of 1.5 μg/day below which the theoretical cancer risk is considered acceptable (less than 1 in 100,000 over a lifetime). This TTC applies to impurities with unknown carcinogenic potency.
For compounds with known carcinogenic potency (including NDMA, NDEA, and other well-characterised nitrosamines), ICH M7 requires use of compound-specific AI limits calculated from TD₅₀ values (dose causing tumours in 50% of animals in lifetime studies).
The mathematical relationship is:
AI (ng/day) = (TD₅₀ × 50,000 ng/mg × 70 kg body weight) / (100,000 × potency factor)
This explains why NDEA’s AI limit (26.5 ng/day) is lower than NDMA’s (96 ng/day) — NDEA has higher carcinogenic potency in animal studies.
Analytical Methods: LC-MS/MS at Parts-Per-Trillion Levels
Testing for nitrosamines at or below regulatory limits requires analytical methods capable of detecting concentrations at the parts-per-billion (ppb) or parts-per-trillion (ppt) level. Conventional HPLC-UV is insufficient for this task. The method of choice is:
LC-MS/MS (Liquid Chromatography-Tandem Mass Spectrometry)
LC-MS/MS couples liquid chromatographic separation with tandem mass spectrometric detection, providing:
Selectivity: Mass-to-charge (m/z) ratio selection in the first quadrupole, fragmentation in the collision cell, and product ion selection in the third quadrupole. This triple-stage filtering eliminates matrix interference that would confound UV detection.
Sensitivity: Modern triple quadrupole instruments achieve limits of detection (LODs) of 0.1–1 ng/mL in pharmaceutical matrices, enabling quantification of nitrosamines at the ppt level in the dosage form.
Specificity via multiple reaction monitoring (MRM): Each nitrosamine is monitored using a unique parent → product ion transition. NDMA, for example, is monitored at m/z 75 → 58 (loss of NO from the molecular ion). False positives are virtually eliminated.
Method Development Considerations
For regulatory submissions, nitrosamine methods must be fully validated per ICH Q2(R1):
- Specificity: Demonstrate resolution from potential interferences in the matrix
- Limit of detection (LOD): Typically 0.1–0.3 ng/mL
- Limit of quantification (LOQ): Typically 0.3–1 ng/mL
- Linearity: R² > 0.999 across the range of 0.5–150% of the specification limit
- Accuracy and precision: ≥ 3 concentrations, ≥ 6 replicates per level
- Robustness: Deliberate variation of chromatographic conditions
- Matrix effects: Evaluate using post-column infusion or standard addition
Headspace-GC-MS is an alternative for volatile nitrosamines (NDMA, NDEA, NDBA) in aqueous matrices, but LC-MS/MS provides broader coverage for the diverse nitrosamine structures relevant to pharmaceuticals.
Sample Preparation
Sample preparation is critical because nitrosamines are present at trace levels in complex matrices. Common approaches include:
- Direct dissolution: For highly sensitive LC-MS/MS systems with sufficient matrix tolerance
- Liquid-liquid extraction (LLE): Using ethyl acetate or dichloromethane to partition nitrosamines from the dosage form matrix
- Solid-phase extraction (SPE): Mixed-mode sorbents for concentrated extracts
- Protein precipitation: For biological matrix applications
Drug Products Most Affected by Nitrosamine Recalls
Sartan antihypertensives: Valsartan, losartan, irbesartan, olmesartan, candesartan — the original class to be recalled. NDMA and NDEA found in API manufactured via the zinc chloride process, where DMF degradation generated dimethylamine.
Ranitidine (Zantac): Unique case of intrinsic instability. NDMA is an inherent degradation product of the ranitidine molecule itself. FDA withdrew ranitidine from all markets in 2020.
Metformin: NDMA found in some metformin batches at levels exceeding the 96 ng/day limit. Recalls issued in multiple countries from 2020 onwards.
Pioglitazone, nizatidine, varenicline: Additional drug classes subject to testing requirements and, in some cases, recalls.
Nitrosamine Testing at Auriga Research
Auriga Research’s analytical team conducts nitrosamine and genotoxic impurity testing using validated LC-MS/MS methods on calibrated triple quadrupole instruments. Our testing covers:
- NDMA, NDEA, NMBA, NIPEA, NDIPA, NDBA, and drug-specific nitrosamines
- Full method development and validation per ICH Q2(R1) for novel compounds
- Risk assessment support per ICH M7 framework
- Stability studies to monitor nitrosamine levels under accelerated and long-term conditions
Our LC-MS/MS capabilities support detection at the 0.1 ng/mL level in complex pharmaceutical matrices. For manufacturers conducting nitrosamine risk assessments or requiring confirmatory testing, contact our pharmaceutical testing team to discuss your specific requirements.
Regulatory timelines for nitrosamine testing are compressed. Early engagement with an experienced testing partner ensures your submission data package is complete, validated, and defensible under regulatory scrutiny.
Auriga Research Team
Auriga Research is India's largest NABL-accredited testing network with laboratories in Delhi, Manesar, Bangalore, Baddi, and Bahadurgarh. Our team of scientists delivers accurate, regulatory-accepted results across pharmaceutical, food, water, environmental, and specialised testing.
About Auriga Research →